ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

Returns on capital

ARS Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-149.9%

avg 27.5%

ROIC

-62.2%

avg -56.6%

ROA

-52.3%

avg -42.5%

Analysis

ROA is currently the strongest return metric at -52.3% versus its period average of -42.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Brian T. Dorsey

Chief Operations OfficerUSD 706.97K57——

Justin Chakma

Chief Business OfficerUSD 682.7K36240.00K0.24%

Alexander A. Fitzpatrick

Chief Legal Officer & SecretaryUSD 677.15K5990.91K0.09%

Eric Karas

Chief Commercial OfficerUSD 618.61K5312.18K0.01%

Daniel Relovsky

Senior Vice President of Marketing————

Donn Casale

CEO, President & Director—531.04M1.04%

Kathleen D. Scott

Chief Financial Officer——240.00K0.24%

Lynda Harris

Vice President of Human Resources————

Robert Bell

Co-Founder & Chief Science Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

2

$283,550.00

Net Transaction Value

−$283,550.00

Net selling

Most Active

Karas Eric

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 12, 26

Karas Eric

Direct

Sell$250K
Jun 12, 26

Fitzpatrick Alexander A

Direct

Sell$33.6K

Summary

Insiders reported 0 buys worth $0.00 and 2 sells worth $283,550.00 over the last 12 months. That adds up to net selling of $283,550.00. Karas Eric was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+300.1%
+33.2% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +300.1% over three years. Forward estimates point to Revenue at +33.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does ARS Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SPRY's management, answered from reported figures.

Who manages SPRY?

ARS Pharmaceuticals, Inc. (SPRY) lists 9 active executives. The top listed executive is Alexander A. Fitzpatrick, Chief Legal Officer & Secretary.

Are SPRY insiders buying or selling?

Recent insider activity shows net buying of $49.44M.